EDITORIAL U nlike many editorials, this one is not a criticism of the referenced study. Rather, the opposite, as the study by Buchkowsky and Jewesson 1 in this issue of The Annals is a nicely done piece of work on a topic that has grown in importance and controversy throughout the health professions in the past couple of decades. It is important to consider the reactions that readers will have to the study. They will range from disinterest, to average interest from people who recognize what was truly stated and no more, to others who will zealously contend that the findings are further proof that any research/publication that has any attachment to industry is worthless, biased drivel. It is this latter reaction that needs consideration, because we are all biased when it comes to science, be it researchers in the laboratory, the Phase I unit, or 19th site of a multicenter trial, or average clinicians who are choosing therapies for their patients. As one of the reviewers of this editorial mentioned, scientists, and clinicians for that matter, do not form hypotheses in a vacuum. All clinicians have biases concerning the best therapy for their patients, even if it is not in concordance with the literature base on the topic. This approach is not sensationalized as "scientific bias." Rather, clinicians are respected for doing what they feel is best for their patients based on anecdotal experiences with the disease or treatment.
However, when it comes to the publication of scientists' results, clinicians and other scientists make wide assump-tions of bias unless the study has ideal methods and outcome measures and is funded by the National Institutes of Health (NIH), another nonprofit organization, or out of the scientist's own pocket. As one author put it in the early 1990s, when disclosure of financial interests was first becoming popular, this disclosure of possible conflicts of interest by authors as well as the funding sources of studies is fostering a modern-day scientific McCarthyism. 2 From the start of flipping to a journal article and seeing that it was sponsored by company XYZ, or that the authors have listed financial/consulting relationships with the company that made the article's drug, or that one of the 10 authors works for company XYZ, readers often assume that there is a significant level of bias in the paper before it is even evaluated for its scientific merits. This assumption that the author(s) have slanted the data or conclusions due to having stock in a company, or because they work for the company, or because the company gave them an unrestricted educational grant is an accusation of scientific dishonesty or even fraud. This reaction by professionals who do not perform research may be excused, as education on proper literature review is waning. However, scientists accusing other scientists without asking the researchers about their results or objectively reviewing the paper based on its scientific merits is despicable, as the act represents the antithesis of the review process as well as our legal system of assumption of innocence until proven guilty.
Because the paper by Buchkowsky and Jewesson has the potential to further this McCarthyistic approach to literature review, it is important to examine what they truly dis-covered. First, they found that documentation of industry sponsorship has increased over the last 20-plus years, whereas non-industry sponsorship has remained, at most, even. This information should not surprise anyone, including the authors, as the majority of journals at the beginning of the data collection period used by Buchkowsky and Jewesson did not require sponsor documentation. Rather, documentation of non-industry sponsors, such as the NIH and special interest groups (eg, American Lung Association), was necessary. This policy changed early in the study's data collection period, resulting in a large increase in documentation of industry support. As it is highly unlikely that the pharmaceutical industry suddenly increased its support of research, journals' requirements for documentation solely explains this increase. The continued increase in studies with industry or mixed industry/non-industry support throughout the 1990s (Figure 1 1 ; see page 581) most likely represents the steady increase in research budgets by major pharmaceutical companies during this period. Increased efforts to work with non-industry groups to defray costs and support research in large (prevention trials) or special (orphan drugs) populations or developing parts of the world also play a role in this increase. In contrast, the decrease of non-industry sponsorship most likely reflects fluctuations in non-industry group financials, as many are dependent on the health of the economy.
The second thing that Buchkowsky and Jewesson demonstrated was that there was a significant increase in the inclusion of industry-based authors. Buchkowsky and Jewesson subsequently stated that, since industry-based authors have a significant interest in seeing their drug do well/look good, they have an increased risk of introducing bias. However, if one were to look at the literature of the last 10 -20 years, industry researchers who have been included as authors have been healthcare professionals rather than marketing executives. Although that does not negate the vested interest in their compound's success, like a private researcher they many times have the same basic desire for conducting scientific research that their non-industry peers will acknowledge.
Ironically, though, Buchkowsky and Jewesson state there are now journals that will not accept papers allowing the sponsor to have sole control of the data. Although not stated specifically, this rule most likely is directed at industry rather than non-industry support/control, even though authors of a paper from a non-industry source may have as little control of the content and have their own bias. If this rule becomes the norm rather than the exception, studies typically done in-house by companies (eg, preclinical, pharmacokinetic characterization, drug interaction) will never be allowed to be published by the industry scientists actually conducting them. To access the data that clinicians will need to use the drug properly/safely, non-industry scientists will have to be contracted to write and publish the study as if it were their own. Alternatively, a medical writer will be hired and the outside scientists will be contracted to put their name on it. Regardless of which approach is taken, what was seen as a way to improve manuscript credibility would, ironically, induce and support scientific dishonesty and fraud.
Although the list of examples such as those presented above may be endless, some truths need considering when evaluating a paper or presentation regardless of its source of support. First, readers of the scientific literature should have at least a modicum of knowledge about what makes a study good or bad and not refute the findings just because someone states that it is biased or was poorly done. If it is a comparative trial, did the researchers use an appropriate comparator? If the trial should have been placebo controlled, would it have been ethical and possible to incorporate a placebo (they are very hard to find unless a company prepares them-especially placebos identical to the test drug)? Did the researchers do intent-to-treat analysis rather than analysis only of the evaluable population? Was blinding used when appropriate? Was study arm patient allocation equal? Were state-of-the-art methods used for outcome measures; if not, was it feasible for them to be used (just because Company XYZ gave an unrestricted grant does not mean it was enough to analyze all measures that would be ideal and by the ideal methods)? Was the study published in a peer-reviewed journal? Second, if bias is detected, was it intentional? Realistically, the majority of work has limited, if any, intentional bias although there are exceptions and they always will exist. Spotting publications/presentations with true bias throughout is simple; such findings can be easily dismissed. However, if one were to discount all data that had any connection to industry, clinicians would be driven back into how medicine was practiced before the pharmaceutical industry was developed. Third, stating that there is significant inherent bias because a study was powered only to show non-inferiority may be naïve. The reader should become aware of the rules and regulations that the manufacturer must follow to conduct the studies necessary for Food and Drug Administration approval. Although continuing to conduct solely non-inferiority studies after approval can be mocked, these trials still provide significant information. For example, a comparison trial of antibiotics may show that, despite a surge of resistance, an older, cheaper agent may still be efficacious compared with a more expensive new agent.
Fourth, in the real world, where can researchers obtain money for their projects? In a review of the list of Requests for Applications for research proposals at the NIH Web site, one would notice that the majority of researchers in the pharmacy profession are not eligible for NIH research monies. In contrast, the money and research contracts for conducting the types of research that pharmacists are trained to do is readily available from industry. The publications and presentations that result from these projects have advanced and will continue to advance science regardless of what a scientific McCarthyist may think.
Finally, if practitioners see bias in a journal or presentations at a meeting, what have they done to curb this bias other than get up at a meeting and tell a speaker that he or she is an industry lapdog? Pharmacy practitioners should become active by joining a meeting's planning committee or volunteering to be a peer reviewer for their favorite journal(s). Although journal editors hold some of the blame, a significant amount of blame for inclusion of a paper that is full of bias rests on the shoulders of the peer reviewers of that manuscript. If a peer reviewer does a cursory job or turns a blind eye for a friend, all who read that paper once it is published are the victims. If peer reviewers do not confront an author over intentional bias, they are a source of its perpetuation and therefore have no right to complain. If the reviewer believes that certain data should or should not be included in a paper, an author who was overruled on the same subject by the project's industry sponsor is empowered to make changes he or she originally wanted. An industry source may have significant initial input into the content of a paper; however, inappropriate input can be suppressed by the work of a good peer reviewer.
How will we know when the healthcare profession finally puts the scientific incarnation of McCarthy to rest and an article can be read and discussed for its merits? The first sign of this will be when visiting students do not state at a journal club that the study's funding source, the authors' employer, or what the authors have in their retirement portfolio is a significant or potentially significant fault. If this is encouraged, science and the publication and presentation of it can get back to what it is all supposed to be about.
